STUDboardsPlay · Research · Self · Fit · Money · Learn · Study · Plan · Token STUDtokenOptional

STUDresearch · Non-peptide

MK-677

Also known as

Ibutamoren · Ibutamoren mesylate · MK-0677 · MK0677 · L-163,191 · LUM-201 · Nutrobal · Oratrope (former tentative brand) · MK677 · MK 677

Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.

Open in the directory ↗
Non-peptide Lots of talk Systemic Oral Growth hormone axis

Systemic — oral non-peptide ghrelin-receptor (GHS-R1a) agonist / GH secretagogue; whole-body GH pulses and circulating IGF-1, not local site targeting.

What people say MK-677 (ibutamoren) is an oral small-molecule ghrelin-receptor agonist and GH secretagogue—not a peptide, SARM or exogenous HGH. It raises GH/IGF-1 during continued use but remains unapproved for adult physique or anti-aging use. Doses people talk about
Seven-week community account12.5 mg daily

The author reported hunger from the first dose, deeper sleep within days and slight water retention during seven weeks, then hand numbness and joint aches after briefly increasing to 25 mg and stopping for a couple of days.

Three-day community account25 mg nightly

The author reported better sleep on day one, facial water retention by day two, normal hunger and a small self-measured fasting-glucose change; follow-up was extremely short.

Common human trial exposure25 mg once daily

Used in older-adult endocrine and body-composition studies; population, formulation and monitoring differ from unsupervised athletic use.

These are descriptive exposures, not titration advice. Trial-grade ibutamoren, gray-market products, short reports and long clinical cohorts are not equivalent evidence contexts.

Half-life & effect duration

Half-life in the body
  • Parent-plasma · secondary estimateAbout 4–6 hours
Felt duration people report
  • Community active-window shorthandAbout 24 hours
  • Hunger reportsFrom the first dose or within 1–3 hours; little hunger in some accounts
  • Other experiencesDeeper sleep within days; water retention building over days to 1–2 weeks
Timing context & sources
How it may feel Hunger and sleep changes may appear within days, while water retention, numbness, lethargy or joint symptoms can emerge later. Inspected 12.5 and 25 mg accounts conflicted, and higher exposure did not reliably mean better tolerance.
Cycles people discuss Community blocks commonly run 8–12 weeks, while human trials ranged from days to about a year. Trial duration in older or clinical populations does not establish long-term safety for unsupervised athletic use. Timing Night dosing is the dominant community habit when sleep is the goal or users want hunger to land overnight; morning use appears when nighttime hunger, reflux or vivid dreams disrupt sleep. This is preference-driven, not a proven superior clock. Stacks SARM, anabolic, GH and peptide stacks can add water, glucose and endocrine effects while destroying attribution. Access talk RUO is the gym path: Capsules and liquids sold as research chemicals / not for human consumption dominate physique talk. That label is not QC. Watch for Insulin sensitivity / glucose: Fasting glucose and insulin can rise; OGTT impairment in obese short trials; Nass ~12 months: fasting glucose +~0.3 mmol/L (~5 mg/dL) average with decreased insulin sensitivity; some subjects move into impaired-fasting-glucose ranges — labs > vibes.
Related
IpamorelinCJC-1295GHRP-2GHRP-6

Tap a line to jump into the full notes. Research only — may be wrong.

Timing context & sources

Half-life in the body

A numerical human parent-plasma half-life was not established from the reviewed accessible primary material.

A human single-dose 5 mg pharmacokinetic paper exists and maps concentration over time, while other human trials use once-daily dosing and 24-hour GH sampling; the accessible abstracts do not supply a terminal half-life value.

The full PK article may contain parameters unavailable in the reviewed abstract. Secondary animal/model estimates and daily schedules cannot replace a human value.

Felt duration people report

Community reports do not establish one dependable hunger, sleep or adverse-effect duration.

A self-reported 17-year-old's 12.5 mg daily account described hunger from the first dose and deeper sleep within days over seven weeks, while a 25 mg nightly three-day account reported sleep and water changes but little hunger.

Anonymous unblinded reports, unverified products, self-measured glucose, different durations and possible promotional context prevent causal or prevalence estimates.

  • Reddit r/SARMsTalk — MK-677 seven-week review/experience (opens in a new tab)A self-reported 17-year-old author described 12.5 mg daily for seven weeks, hunger from the first dose, deeper sleep within days and slight water retention; after doubling to 25 mg, hand numbness and joint aches prompted stopping for a couple of days.Anonymous unblinded self-report by a self-reported 17-year-old, with an unverified product and possible community promotional context; symptom attribution and glucose interpretation were not clinically verified.
  • Reddit r/SARMs — MK-677 25 mg (opens in a new tab)Three-day 25 mg nightly report described better sleep on day one, facial water retention on day two, normal hunger and fasting glucose self-readings of 82 then 86 mg/dL.Extremely short anonymous report with unverified product, uncontrolled diet and self-measured glucose; cannot establish risk, efficacy or persistence.

Other context in this card

What people say 17

  • Sleep feel (logs): Deeper/more restorative sleep frequently reported within nights 1–14; some also get morning grogginess or vivid dreams from the same pathway. forum
  • Appetite: Strongest, most consistent community effect — ghrelin-mimetic hunger used deliberately by hard gainers; cutters often call it the main downside. Trial commentary also notes increased appetite that can partially subside over months. forum
  • Recovery feel: Multi-week logs claim easier day-to-day recovery and training continuity — heavily confounded by sleep + surplus calories. forum
  • Fuller / skin look: Some logs claim better skin or “full” muscle look; hard to split from intramuscular/extracellular water, glycogen, and calories. anecdote
  • Vs injectables (preference): Chosen for once-daily oral convenience vs multi-dose GHRP/GHRH or expensive rhGH — not because it “beats” pharma GH head-to-head in athletes. forum
  • IGF-1 as a “is this real” test: Logs that bother with bloodwork use an IGF-1 rise to sanity-check gray bottles — no rise after weeks is treated as fake-or-underdosed talk, not a new mechanism. forum
  • Sleep architecture (strongest non-anecdote win): Copinschi et al. (polysomnography, ~25 mg bedtime context): Stage IV / slow-wave sleep up ~50% in young subjects; REM up ~20% in young / ~50% in older with faster REM onset — heavily cited across guides. trial
  • Nitrogen / anti-catabolism: Murphy et al. (1998): calorically restricted adults (~18 kcal/kg·day) on 25 mg/day improved integrated nitrogen balance over 7 days vs placebo — core “preserve lean in a cut” talking point (short-term, diet-stress context). trial
  • Fat-free mass (obese men): Svensson et al. ~8 weeks @ 25 mg: significant FFM increase (DEXA / multi-compartment methods in the series); total and visceral fat not cleanly reduced as a fat-loss drug; OGTT showed impaired glucose homeostasis. trial
  • Fat-free mass (older adults): Nass et al. (2008) long oral ghrelin-mimetic RCT at 25 mg daily: FFM rose ~1.1 kg (CI ~0.7–1.5) vs placebo ~−0.5 kg over ~12 months; body weight +~2.7 kg MK vs +~0.8 kg placebo; strength/function gains were not the headline win. Two-year exploratory analyses broadly confirmed year-1 hormonal/body-comp pattern. trial
  • IGF-1 elevation: Continued oral dosing reliably raises circulating IGF-1. Examples commonly quoted: Chapman-era elderly ~141 → ~265 mcg/L at 4 weeks on 25 mg (young-adult range restoration narrative); obese/short studies often ~40%+ class rises; elderly/GHD-leaning cohorts can show larger % rises depending on baseline and duration. trial
  • GH secretion: Chapman-era and related elderly/young data: mean 24-h GH up substantially at 10 mg and higher at 25 mg bands; pulsatile pattern preserved more than flat exogenous GH — bro “keeps your own pulses” pitch. trial
  • No clear tachyphylaxis on GH/IGF-1 (long use): Nass-style multi-month to ~2-year data framed as sustained GH/IGF-1 elevation while dosing continues — undercuts pure “must cycle every 4 weeks or receptors die” lore, though community still cycles for sides/appetite/labs. trial
  • Bone discussion: Oral MK-677 raised bone-turnover markers (formation and resorption markers up in elderly/osteoporosis-adjacent work). Murphy et al. combo osteoporosis trial: MK-677 + alendronate increased femoral-neck BMD ~4.2% vs ~2.5% alendronate alone at ~18 months — similar enhancement not cleanly seen at all sites. Gym users almost never measure BMD. trial
  • Energy expenditure (transient): Obese 8-week study saw basal metabolic rate up at 2 weeks but not clearly sustained at 8 weeks — weak “fat burner” story. trial
  • Cortisol / PRL relative to GHRPs: Bro lore often prefers MK over GHRP-2/6 or hexarelin for less dramatic cortisol/prolactin spikes; trials still show some PRL rise (especially early) and measurable cortisol signals (e.g., Nass reported mean cortisol increase) — not zero endocrine noise. trial
  • What trials did not show as primary wins: Clean standalone fat loss, large strength/function gains in elderly Nass population, or a free pass on glucose/edema. trial

Doses people talk about 21

  • Inspected reports plus broader community band: One seven-week account reported 12.5 mg daily before a brief increase to 25 mg; another short account reported 25 mg nightly for three days. Broader community charts remain ~10–25 mg, often nightly. forum
  • Beginner / side-control band (community): ~10–15 mg once daily to test hunger, water, lethargy, and morning glucose feel before climbing. forum
  • Very low “feel it” / sleep-only talk: Some logs run ~5–10 mg for sleep goals; clinical sleep architecture data still largely anchored near 25 mg. forum
  • Common physique band: 20–25 mg once daily — modal bodybuilding / research-chem discussion range aligned with trial dose. forum
  • “Sweet spot” talk: Many coaches/logs call ~20–25 mg enough; aggressive push past 25 mg often framed as more sides for diminishing GH/IGF returns. forum
  • Upper community band: 30–50 mg/day in aggressive logs; more hunger, edema, lethargy, and glucose talk; diminishing-returns arguments common above 25 mg. forum
  • Female community talk: Often ~5–15 mg (sometimes up to ~20 mg) in secondary guides and logs — lower start for hunger/edema/glucose caution; primary controlled female physique data is thin. forum
  • Split dosing debate: Minority run e.g. 10–12.5 mg AM + 10–12.5 mg PM (or 10+10) for smoother appetite/lethargy; majority stick to once daily because of long practical IGF-1 coverage. forum
  • Bedtime (most common): Align with nocturnal GH pulse lore + push peak munchies into sleep; preferred when sleep is the primary goal. forum
  • Morning dosing: Used when bulkers want all-day hunger or when nighttime hunger/reflux/vivid dreams wreck sleep; tradeoff is daytime appetite and weaker “sleep synergy” narrative. forum
  • Empty stomach talk: Many research-protocol summaries prefer evening dose ≥2 h after last meal (food can blunt GH response pathways); others say food does not kill the practical effect — preference varies more than hard PK law in forums. forum
  • Liquid vs capsule: Liquids allow 5 mg titration and split doses; capsules/tablets simpler (12.5 mg and 25 mg counts common on vendor shelves); both oral — no peptide units math. forum
  • 12.5 vs 25 camp (2025–26): 25 mg is the trial copy; a growing camp parks at 10–12.5 mg for sleep/IGF with less hunger and water. 5-on-2-off at 12.5 is emerging folklore, not a study arm. forum
  • Women’s band: 5–12.5 mg is the loud start; hunger and face-puff get called harder when copying a male 25 mg chart. PCOS/glucose caution is the extra women’s-thread watch. forum
  • Titration practice: Start 10–12.5 mg → hold 1–2 weeks → step toward 20–25 mg only if sides allow; reverse steps for edema/glucose/lethargy. forum
  • Purity / label mg flag: Research-chem ibutamoren content and identity vary; labeled 25 mg is not third-party proof. forum
  • Trial lower band: 10 mg daily appears in elderly/GHD-axis and dose-response work; still raised GH/IGF-1, usually less than 25 mg. trial
  • Trial very-low exploration: Doses as low as ~2–5 mg/day appear in some sleep/exploratory designs; not the physique modal dose. trial
  • Trial upper exploration: 50 mg daily used in short periods in some clinical/exploratory designs (e.g., GHD adult titration segments; Murphy rising-dose style 25 mg then 50 mg periods in secondary summaries); highest commonly cited researched daily dose — not a “standard gym target.” trial
  • Framing: Discussed research/community ranges only — not medical advice, not prescriptions, not safety-validated athletic protocols. forum
  • Trial anchor (modal clinical): 25 mg once daily is the most-cited human study dose (sleep, obese FFM, older-adult body-comp, many GH/IGF-1 papers, hip-fracture recovery design). trial

How it may feel 9

  • Hours 1–4 after dose: Hunger onset common (especially if dosed morning/fed); Tmax often discussed ~1–3 h; some feel mild sedation or “ready for bed” if dosed evening. forum
  • Days 1–7: Sleep change and appetite spike are the earliest signals; mild lethargy or water feel starts for a subset; GH pulses amplify before body-comp changes. forum
  • Weeks 3–4 community checkpoint: Is hunger/edema/lethargy/glucose worth the sleep/recovery benefit? Many settle dose here (cut toward 10–15 mg or switch AM/PM). forum
  • Months 2–3: “Set and forget” sleep/recovery users common; bulkers continue; recomp claims get noisy without tracking calories; trial commentary notes appetite sometimes eases after a few months while gym hunger complaints often persist. forum
  • Hunger first, glucose later: Nights 1–14 are ravenous + deep sleep. Water/puff is weeks 1–4. Fasting-glucose drift is the week 8–12 “only shows on a panel” complaint. forum
  • Weeks 1–2: Facial puffiness, ring/finger tightness, ankle water, and a few lbs on the scale common (community often cites ~2–5 lb water class); appetite stays high; OGTT-type glucose impairment appeared by 2 weeks in obese trial context. trial
  • Weeks 2–4: IGF-1 often approaching steady elevated range in trial kinetics (Chapman-style 4-week IGF-1 checkpoint); recovery-feel talk starts; joint stiffness / carpal-tunnel-like tingling appears for some. trial
  • Weeks 4–8: Bulk logs that hit surplus report size/weight; cutters often struggle adherence; FFM signal in 8-week obese trial sits in this window (water + lean mix). trial
  • Months 3–12+: Nass-style long use keeps GH/IGF-1 elevated while on drug; FFM advantage can accumulate over months in older adults without matching strength/function wins; bone remodeling talk is multi-month. trial

Around the dose 6

  • Clock: Night is the default because of sleep/hunger. Morning exists for people who hate night hunger. forum
  • Food: Expect hunger. Protein-forward meals get mentioned so the hunger doesn’t become a junk binge. forum
  • Training: Not a pre-workout. Water and sleepy-feeling are why people don’t take it 20 minutes before a session. forum
  • Sleep: A reason people pick night. Fasting windows fight MK hunger — a common quit reason. forum
  • Glucose talk: Fasted morning glucose chatter is why some move the dose or add walks. forum
  • Bloodwork talk: IGF-1 (is the bottle doing anything) and fasting glucose / insulin / HbA1c (the bill). Not a DIY protocol — what threads actually compare. forum

Cycles people discuss 11

  • Typical physique cycle: 8–12 weeks on is the most-repeated community block; 12–16 weeks also common for bulk-oriented runs. forum
  • Short research-chem chart: Some guides mirror short trial blocks: ~2–8 weeks on → 2–4 weeks off (washout for water, appetite, fasting glucose recheck). forum
  • On/off template (forum charts): Often 8–12 weeks on → ~4 weeks off (or 2–4 weeks washout) to drop water, reset appetite, and recheck fasting glucose/insulin/HbA1c. forum
  • Bulk vs cut length: Bulkers tolerate longer runs; cutters often shorten or drop when hunger destroys deficit adherence despite nitrogen-balance theory. forum
  • PCT (alone): Broad consensus that MK-677 alone does not suppress HPG axis / testosterone the way AAS or many SARMs do — dedicated SERM/PCT “for MK only” is generally called unnecessary. forum
  • PCT (stacked): If stacked with suppressive SARMs/steroids, PCT talk follows the other compounds — not MK. forum
  • Re-runs: Restarts after breaks are common; water and hunger often return quickly on reintroduction. forum
  • Goal-based exit: Stop or deload when edema, glucose labs, lethargy, uncontrolled fat gain, or cardiac risk flags outweigh sleep/recovery benefits. forum
  • Longer / lifestyle use: 3–6+ months continuous (sometimes until sides force stop) for sleep/recovery “set and forget”; clinical older-adult work ran to ~12 months with 2-year exploratory follow-on; bone combo work ran toward ~18 months. trial
  • Desensitization debate: Forums sometimes cycle “to prevent tolerance.” Hormonal data from long Nass use is framed as sustained GH/IGF-1 without classic tachyphylaxis — cycle rationale is more about sides, appetite control, and metabolic labs than proven receptor death. trial
  • Multi-year unsupervised athletic safety: Not established — long clinical windows still are not young-athlete blast culture. trial

Timing 10

  • Appetite timing: Hunger often within 1–3 hours of a dose; bedtime dosing is a strategy to sleep through the worst spike. forum
  • Water lag: Edema and scale water typically build over days to ~1–2 weeks, not after a single pill. forum
  • After stop: Appetite and fluid settle over days to a few weeks; IGF-1 drifts down toward baseline without an abrupt mandatory “crash” narrative. forum
  • Vs short secretagogues: Injectable GHRPs/ipamorelin are short pulses (hours); MK is the oral “all-day baseline GH/IGF tone” tool in stack lore. forum
  • Parent-plasma half-life: Secondary animal/modeling summaries repeat ~4–6 hours, but the reviewed human 5 mg pharmacokinetic paper's accessible abstract did not provide a numerical half-life. Once-daily human dosing does not establish the missing value. trial
  • Bro “~24 h half-life” shorthand: Forums and many secondary guides say “half-life ~24 h.” More precise framing: long pharmacodynamic / IGF-1 effect supporting QD dosing — not necessarily a 24 h plasma terminal t½. Both numbers circulate; do not collapse them. forum
  • IGF-1 and daily schedules: Human studies show higher IGF-1 during continued once-daily dosing and collect 24-hour GH profiles, but the reviewed sources did not establish that a single oral dose keeps IGF-1 elevated for exactly 24 hours. trial
  • Oral bioavailability: Commonly cited ~60%+ (sometimes ~60–80% in secondary PK writeups) — core reason MK is the practical oral GHS vs injectable peptides. trial
  • Tmax: Often discussed ~1–3 hours post-dose — lines up with early hunger/sedation reports. trial
  • GH vs IGF-1 timing: Acute GH pulse amplification after doses; IGF-1 climbs over multi-day/week continued use and is the usual blood marker people track. trial

More on what it is 10

  • Bro translation: Oral GH secretagogue people use for hunger, sleep, and “looksmax water/fullness” — not a SARM. forum
  • Why people search it: Among the most-mentioned oral “GH axis” compounds for deeper sleep, ravenous appetite (bulk), recovery feel, and lean-mass / IGF-1 talk without daily injections. forum
  • Research lens: Scale weight and “pumps” are confounded by water and calories; hunger is pharmacological (ghrelin path), not willpower failure. Separate trial endpoints (FFM by DEXA/4-compartment, polysomnography, nitrogen balance) from forum bulk logs. forum
  • 2026 access: No approved adult product. Gym talk is research-chem capsules/liquids labeled not-for-human-use; compounding eligibility is argued, not a pharmacy pen. Hidden-in-supplement recalls are part of the watch-for. forum
  • What it is: Oral small-molecule GH secretagogue (ghrelin mimetic / GHS-R1a agonist). Merck developmental codes MK-677 / MK-0677 / L-163,191; rebranded LUM-201 in pediatric GHD programs (Lumos). Not a peptide, not a SARM, not exogenous HGH. trial
  • Mechanism (plain): Agonizes the ghrelin receptor (GHS-R1a), amplifying pulsatile pituitary GH release; circulating IGF-1 rises with continued daily oral use. Human trials commonly used once-daily schedules, but the reviewed sources did not establish that one dose keeps IGF-1 elevated for exactly 24 hours. trial
  • Evidence posture: Multiple human trials (elderly body-comp, obese body-comp, short calorie-restriction nitrogen balance, sleep architecture, bone markers, hip-fracture recovery, pediatric GHD). Long-term unsupervised athletic safety and gray-market product quality remain weak. trial
  • Development reality: Adult physique/anti-aging use is off-label/investigational. Merck adult programs did not yield an approved adult product; a hip-fracture recovery trial was terminated early after a congestive-heart-failure safety signal. LUM-201 continues as a separate oral PGHD research path. trial
  • Not a: Not exogenous HGH, not a steroid, not FDA-approved for bodybuilding or “anti-aging,” not an injectable peptide protocol, not the same risk class as GHRP-6 for acute cortisol/PRL spikes (but not endocrine-silent). trial
  • Regulatory note: WADA lists ibutamoren / GH secretagogues (prohibited in and out of competition). FDA/anti-doping risk pages flag significant safety concerns (CHF signal, metabolic effects). Still investigational for most adult physique uses. trial

Stacks 14

  • Bulk classic: MK-677 + calorie surplus ± mild oral anabolics/SARMs — sleep + hunger + size narrative. forum
  • Other SARM pairings: RAD-140, ostarine (MK-2866), S-23, etc. appear in forum “GH oral + SARM” templates; suppression/PCT driven by the SARM, metabolic/edema load stacked. forum
  • CJC-1295 (no DAC / Mod GRF 1-29) + Ipamorelin + MK-677: Popular “pulses + oral baseline” triple. Example secondary protocol charts (not trials): ~100 mcg CJC no-DAC + ~100 mcg ipamorelin 1–2×/day SC + MK 12.5–25 mg oral at night for 12–16 weeks. Injectables for discrete GH spikes, MK for all-day IGF-1/appetite/sleep; confounded and expensive; start-one-then-add lore common. forum
  • CJC-1295 DAC adjacency: Less clean pulse stacking than no-DAC + ipa; still discussed as GH-axis pile-on with MK (weekly DAC + daily MK). forum
  • GHRP-2 / GHRP-6 + MK: Hunger-on-hunger (especially GHRP-6); many prefer ipamorelin instead to limit cortisol/PRL/appetite stacking. forum
  • Hexarelin caution stack: Stronger GHRP; desensitization and cardiac/PRL talk make “hex + MK forever” less fashionable than ipa stacks. forum
  • vs exogenous HGH: Sometimes used as cheaper oral substitute; sometimes layered under low-dose GH (e.g., 1–2 IU rhGH + 10–25 mg MK lore) — dual GH-axis load raises edema/glucose concern in logs. forum
  • Tesamorelin / sermorelin adjacency: Clinical GHRH analogs discussed as alternate or combo GH-axis tools; different regulatory/access paths than research-chem MK. forum
  • Glucose counter-talk: Berberine, metformin (Rx contexts only), inositol, cinnamon, lower evening carbs, walking after meals — not standardized protocols; monitoring fasting glucose/HbA1c/insulin is the recurring advice theme. forum
  • Recovery adjacency: BPC-157 / TB-500 / “Wolverine” for injuries beside MK for systemic recovery/sleep — complementary goals, not proven synergy. forum
  • Sleep stack hygiene: Magnesium, dark room, fixed bedtime, low alcohol often credited alongside MK when sleep logs look good. forum
  • Creatine overlap: Both can add scale water; users sometimes mis-attribute puffiness. forum
  • Do not stack blindly for “more GH”: Community caution that piling MK + GHRPs + GH multiplies sides faster than results; one axis change at a time is common coach talk. forum
  • LGD-4033 + MK-677 (documented co-admin): Cardaci et al. 2022 case: ~10 mg LGD-4033 + ~15 mg MK-677 daily for ~5 weeks — body mass, lean mass, and fat mass all rose; negative signals reported on bone, lipids, liver enzymes, testosterone — cited as caution, not a green light. trial

Access talk 8

  • RUO is the gym path: Capsules and liquids sold as research chemicals / not for human consumption dominate physique talk. That label is not QC. forum
  • Not a SARM, not a supplement: Mis-shelved next to RAD/LGD in shops; DSHEA does not make ibutamoren a legal dietary ingredient. forum
  • Compounding argument: 2026 threads argue whether ibutamoren sits on a do-not-compound list or is simply never a 503A bulk. Either way, most logs are not pharmacy-dispensed Egrifta-style product. forum
  • Prescription vs gray: There is no routine adult prescription. Clinic “GH-axis” talk is usually other secretagogues; MK-677 remains research-chem culture. forum
  • No approved adult product: Merck programs did not yield a marketed adult drug. LUM-201 is a separate pediatric GHD research path — not the gym bottle. trial
  • Hidden-in-supplement recalls: A 2025–26 kids “growth” product recall after FDA testing found undeclared ibutamoren is the “you don’t always know what’s in the bottle” headline. trial
  • Spiked gray capsules: Overseas testing has found MK-677-labeled capsules containing an undeclared oral anabolic — source risk, not a new MK mechanism. trial
  • WADA: Prohibited GH secretagogue in and out of competition — tested-sport risk is practical. trial

Storage notes 2

  • No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
  • Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum

Watch for 28

  • Appetite (signature): Pharmacologic hunger; primary reason cutters drop it and bulkers keep it — can drive fat gain if surplus is uncontrolled. forum
  • Lethargy / daytime sedation: Subset report “ready to nap,” flat motivation; bedtime dosing or dose reduction is the usual community response. forum
  • Night sweats / dry skin / facial flushing: Appear in secondary research summaries and logs (flushing sometimes described as brief minutes-scale). forum
  • Sleep apnea concern (theory/anecdote): Soft-tissue/fluid changes theoretically unhelpful for OSA — discussed more as caution than proven epidemic. anecdote
  • IGF-1 / malignancy theory: Sustained IGF-1 elevation raises theoretical concern if active cancer history; community absolute contraindication talk, not a measured gym incidence rate. forum
  • Source quality: Gray-market mislabeling and underdosing independent of trial-grade ibutamoren; “feels weak” may be fake product. forum
  • Who often avoids in discussion: Uncontrolled diabetics/prediabetics without monitoring, heart-failure or significant cardiac-risk histories, active malignancy concerns, competitive tested athletes, people who cannot afford appetite-driven fat gain, unsupervised minors (pediatric use is a separate clinical LUM-201 path only). forum
  • Labs commonly discussed if someone is already in a research/medical monitoring frame: Fasting glucose, fasting insulin, HbA1c, IGF-1, basic metabolic panel, lipids, blood pressure, and symptom watch for edema/CTS — not a DIY protocol, just what threads repeatedly mention. forum
  • Hunger is the feature/bug: Bulking loves it; cutting hates it — same compound, different goals. forum
  • Compounding vs RUO: Not an approved adult drug; 2026 threads argue compounding-list status while most physique use stays research-chem labeled not-for-human-use. forum
  • Women / PCOS glucose: Hunger plus an insulin-sensitivity hit is why women’s threads treat fasting glucose as non-optional watch-for, especially with PCOS talk. forum
  • Water retention / edema: Face, hands, ankles, ring tightness, several lbs scale weight; GH-related sodium/fluid shifts; often weeks 1–2 onset; Nass noted transient mild lower-extremity edema as a frequent effect. trial
  • Insulin sensitivity / glucose: Fasting glucose and insulin can rise; OGTT impairment in obese short trials; Nass ~12 months: fasting glucose +~0.3 mmol/L (~5 mg/dL) average with decreased insulin sensitivity; some subjects move into impaired-fasting-glucose ranges — labs > vibes. trial
  • Type 2 diabetes risk talk: Extended use concern in medical/anti-doping explainers — especially prediabetic users; baseline and on-cycle fasting glucose, insulin, HbA1c monitoring is the recurring theme. trial
  • Muscle pain / joint stiffness: Transient myalgia and joint aches appear in trials and logs (Nass listed muscle pain among frequent sides). trial
  • Numbness / tingling: Extremity paresthesias and carpal-tunnel-like symptoms reported (GH-related soft-tissue/fluid pattern). trial
  • Prolactin: Some elevation documented (especially early dosing windows); usually framed as milder than classic GHRPs but not “PRL-proof.” trial
  • Cortisol: Early/transient signals in some designs; Nass reported mean cortisol increase on MK; multi-week obese study did not show sustained serum/urinary cortisol increase at 2 and 8 weeks vs placebo in that specific design — mixed picture, not “zero cortisol.” trial
  • Headache, nausea, diarrhea, abdominal pain, anxiety/mood: Listed across trial AE tables and consumer safety pages; individual reports vary. trial
  • Cardiac / CHF caution (trial-critical): Hip-fracture recovery program (elderly) terminated early after congestive-heart-failure safety signal — secondary summaries often quote ~6.5% MK vs ~1.7% placebo class figures in the stopped cohort. FDA/anti-doping pages cite CHF risk language for ibutamoren. Fluid retention is the mechanistic concern in heart-failure contexts — not a casual “run it anyway” compound for cardiac-risk populations. trial
  • Bone nuance: Turnover markers can rise; site-specific BMD stories are mixed (combo alendronate help at femoral neck in one trial; not “bones only improve everywhere”). Do not assume pure bone benefit. trial
  • LDL / lipids: Nass reported relative LDL decrease vs baseline in MK group — not a free metabolic pass given glucose hit. trial
  • LGD stack lab hits: Co-use with LGD-4033 in controlled case work worsened lipids/liver enzymes/testosterone/bone metrics alongside mass gains — stack risk is real in literature, not only forums. trial
  • WADA / tested sport: Prohibited GH secretagogue — positive tests and sanctions are a practical risk, not theoretical. trial
  • Not risk-free framing: Sleep and recovery wins still pair with hunger, edema, metabolic caveats, and a serious CHF signal in vulnerable elderly trial context; long unsupervised athletic use is evidence-thin. forum
  • Hip-fracture trial CHF signal: A clinical program in older adults raised concern for higher congestive heart failure signal vs placebo (~mid-single-digit % vs ~low-single-digit % in discussions of the terminated hip-fracture context) — major caution in longevity/bro use debates. trial
  • Edema / insulin effects: Water retention and fasting glucose/insulin worsening are recurring medical and community themes. trial
  • Gray bottle / spiked product: 2026 regulator notes include undeclared ibutamoren in a kids “growth” supplement recall and at least one overseas MK-677 capsule lot found to contain an undeclared oral steroid — identity is the risk. trial

Updated: 2026-09-01

Evidence mix Mixed trial + community tags Full: every bullet (trial + community). Use Scan for a faster bro-science read.
↑ Back to top

All STUDresearch topics →